News
Novo Nordisk manufactures much of its GLP-1 drugs in Denmark. The president delayed implementation of the tariff over the ...
Novo Nordisk should perform well thanks to new leadership and a strong underlying business. Exelixis' main oncology franchise ...
Abbott published findings from the AVEIR DR i2i study evaluating the company's novel dual-chamber leadless pacemaker (LP) ...
3d
Zacks Investment Research on MSNNovo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...
1d
Futurism on MSNThis Sleazy GLP-1 Prescription Site Is Using Deepfaked "Before-and-After" Photos of Fake Patients, and Running Ads Showing AI-Generated Ozempic BoxesMEDVi, an online hub for GLP-1 drugs, wants you to know that it's "serious" about helping you lose weight. According to its ...
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...
Despite the price drops, the drugs remain costly. Novo Nordisk cut the price of Wegovy by 23 percent for cash payments from ...
1d
Medical Device Network on MSNHistoSonics’ histotripsy system receives early market access authorisation in UKHistoSonics' Edison histotripsy system has been granted controlled early limited market access in the UK under an Unmet ...
2d
Medical Device Network on MSNCEO maligns FDA delays over depression device treatments’ US market entryThe CEO of Flow Neuroscience has called out the US Food and Drug Administration (FDA) for market entry delays for clinically ...
19h
Zacks Investment Research on MSNHims & Hers vs. Amwell: Which Telehealth Stock Is the Better Buy?Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space ...
"Being linked to 'Ozempic face' inducing changes to the mouth, teeth, gums and surrounding facial structures due to the rapid ...
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results